Abstract
To observe the eradication rate, safety and compliance of bismuth quadruple therapies based on minocycline in the newly diagnosed patients with Helicobacter pylori (Hp) infection. We selected 150 penicillin allergic patients for the initial treatment of Hp infection treated in Beijing Jishuitan hospital from January 2018 to February 2019. Subsequently, the patients were randomly selected into the minocycline and metronidazole-containing group (RMMB) and minocycline and levofloxacin-containing group (RMLB). The total course of treatment is 14 days. Follow-up clinical manifestations 3 to 5 days after treatment. The 13C urea breath test was performed 4 to 12 weeks to confirm the eradication of Hp. There were no significant differences in baseline data between the two groups (p>0.05). According to ITT analysis, the eradication rates of RMMB group and RMLB group were 80.3% (61/76) and 89.2% (66/74), respectively (χ2=2.301, p=0.129). According to PP analysis, the eradication rates of the RMMB group and the RMLB group were 83.6% (61/73) and 90.4% (66/73), respectively (χ2=1.513, p=0.21). The overall incidences of adverse events were 47.4% and 38.8% in the RMMB and RMLB groups, respectively (p=0.924). In patients with penicillin allergy, the eradication rate of minocycline-based bismuth quadruple therapies is ideal and the side effects are few. It is recommended for the eradication treatment of Hp-infected patients with penicillin allergy.
Highlights
Helicobacter pylori (Hp) infection is a global disease
Exclusion criteria: (1) taking drugs that may affect the results of the study 4 weeks before enrollment, such as proton pump inhibitors (PPIs), bismuth or antibiotics; (2) patients with malignant tumors; (3) history of upper gastrointestinal surgery patients; (4) patients with systemic diseases such as severe liver and kidney damage; (5) those who are allergic to the drugs used in this study; (6) pregnant and lactating women; (7) long-term use of glucocorticoids or nonsteroidal anti-inflammatory medicine patient
The results of this study showed that in patients with Helicobacter pylori infection allergic to penicillin, the minocycline-containing bismuth quadruple therapies achieved more than 80% eradication
Summary
Helicobacter pylori (Hp) infection is a global disease. It has attracted attention due to peptic ulcer, gastric cancer, gastric mucosa-associated lymphoid tissue (MALT) lymphoma and other intra- and extra-gastric diseases (The Chinese Society of Digestive Diseases, 2017). In recent years, due to the increased resistance rate of Hp to various antibiotics, eradication therapy has become more and more difficult. For patients who are allergic to penicillin, there is a lack of ideal treatment options. Tetracycline is recommended as a replacement for amoxicillin for eradication therapy in patients with allergies to penicillin (The Chinese Society of Digestive Diseases, 2017). Minocycline is a semi-synthetic tetracycline with fewer side effects. Our previous study showed that the bismuth quadruple therapies with minocycline/amoxicillin has a good eradication effect on patients with Hp retreatment (Zhang et al, 2015a, 2017). This study intends to use minocycline instead of tetracycline to observe the eradication effect of minocycline combined with metronidazole and fluoroquinolone on patients allergic to penicillin
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
